Adjustable Vocal Implant System ( VOIS ) for Unilateral Vocal Fold Paralysis: Short‐Term Outcomes From a 12‐Patient Case Series

Background Unilateral vocal cord palsy (UVCP) significantly affects phonation and swallowing. While injection laryngoplasty and medialisation thyroplasty are effective, both may require revision. Vocal Implant System (VOIS; APrevent Biotech GmbH) is an adjustable titanium‐silicone thyroplasty implant that allows postoperative modification, potentially reducing the need for further surgery. Methods Twelve patients, seven male and five female, underwent VOIS implantation. Voice outcomes were assessed pre‐ and postoperatively using the GRBAS scale and the Voice Handicap Index‐10 (VHI‐10). Results The composite GRBAS score improved significantly from 9.0 ± 1.87 to 3.75 ± 2.49 ( p = 0.0024). The VHI‐10 decreased from 25.75 ± 9.36 to 14.92 ± 9.55 ( p = 0.0093). No intra‐ or postoperative complications occurred. Two patients required postoperative implant volume adjustments—one performed in clinic and one under local anaesthetic in theatre. Conclusion The VOIS implant thyroplasty demonstrated significant improvement in both perceptual and patient‐reported voice outcomes with a favourable safety profile. Larger, long‐term studies are warranted to confirm its comparative efficacy and durability.